Nkarta to present data on B-cell depleting therapy at rheumatology meeting

SOUTH SAN FRANCISCO - Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company with a market capitalization of $164 million, will present clinical data on its investigational natural killer (NK) cell therapy, NKX019, at the American College of Rheumatology Convergence 2025 meeting in Chicago on Sunday, October 26. According to InvestingPro data, while the company maintains a strong cash position relative to its debt, it faces challenges with rapid cash burn.

According to a press release, the presentation will showcase data demonstrating that NKX019 achieved B-cell depletion followed by reconstitution of the B cell compartment in participants with non-Hodgkin lymphoma. The company will also present preclinical data showing the therapy’s effectiveness in depleting pathogenic B cells in both lymphoma and autoimmune disease models. Despite recent market volatility that has led to a 12.5% decline in share price over the past week, analysts maintain optimistic price targets ranging from $8 to $18.

The poster, titled "NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease," will be presented by Mira Tohmé, associate director of translational research at Nkarta.

NKX019 is an engineered, allogeneic NK cell therapy targeting CD19, a protein found on B cells. The company states that the therapy traffics to lymphoid organs and disseminates across multiple tissues.

"Our data highlight the potential for our engineered, allogeneic NK cells to treat a range of autoimmune diseases by selectively depleting the disease-driving B cells without inducing limiting toxicities," said Tohmé in the statement.

Nkarta is a clinical-stage biotechnology company developing allogeneic, off-the-shelf NK cell therapies for autoimmune diseases. The company will also have an exhibition booth at the conference where attendees can discuss its clinical programs. InvestingPro analysis indicates the company maintains a healthy current ratio of 15.67, suggesting strong short-term financial stability. For deeper insights into Nkarta’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.